Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: A review of preclinical and clinical data

Clinical Therapeutics

Volumn 34, Issue 3, 2012, Pages 521-536

  Dempster, David W ^a   Lambing, Cheryl L ^b   Kostenuik, Paul J ^c   Grauer, Andreas ^c  

^a HELEN HAYES HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMGEN INC   (United States)

Author keywords

Denosumab; Osteoporosis; RANK; RANK ligand; RANKL

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO;

BONE DENSITY; BONE DISEASE; BONE MASS; BONE METASTASIS; BONE NECROSIS; BONE STRENGTH; CARDIOVASCULAR DISEASE; CELLULITIS; CLINICAL TRIAL; CONCUSSION; DRUG MEGADOSE; DRUG WITHDRAWAL; ECZEMA; FALLING; FLATULENCE; FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; HYPOCALCEMIA; INFECTION; ISCHEMIC HEART DISEASE; NEOPLASM; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PERIPHERAL VASCULAR DISEASE; POSTMENOPAUSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; STROKE;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE AND BONES; BONE DENSITY; BONE REMODELING; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ESTROGENS; FEMALE; HUMANS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RANK LIGAND; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84858590521     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.02.002     Document Type: Review

References (84)

1. Dempster D.W. Anatomy and functions of the adult skeleton. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 2006, 7:11. The American Society for Bone and Mineral Research, Washington, DC. 6th ed. M.J. Favus (Ed.).
2. Uthgenannt B.A., Kramer M.H., Hwu J.A., et al. Skeletal self-repair: stress fracture healing by rapid formation and densification of woven bone. J Bone Miner Res 2007, 22:1548-1556.
3. Frost H.M. Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res 1969, 3:211-237.
4. Takahashi H., Hattner R., Epker B.N., Frost H.M. Evidence that bone resorption precedes formation at the cellular level. Henry Ford Hosp Med Bull 1964, 12:359-364.
5. Darby A.J., Meunier P.J. Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis. Calcif Tissue Int 1981, 33:199-204.
6. Parfitt A.M., Mathews C.H., Villanueva A.R., et al. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 1983, 72:1396-1409.
7. Eriksen E.F. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 1986, 7:379-408.
8. Aloia J.F., Arunabh-Talwar S., Pollack S., Yeh J.K. The remodeling transient and the calcium economy. Osteoporos Int 2008, 19:1001-1009.
9. Parfitt A.M. Morphological basis of bone mineral measurements transient and steady state effects of treatment in osteoporosis. Miner Electrolyte Metab 1980, 4:273-287.
10. Yuan Y.Y., Kostenuik P.J., Ominsky M.S., et al. Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease. Osteoporos Int 2008, 19:625-635.
11. Recker R., Lappe J., Davies K.M., Heaney R. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 2004, 19:1628-1633.
12. Eghbali-Fatourechi G., Khosla S., Sanyal A., et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-1230.
13. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
14. Yasuda H., Shima N., Nakagawa N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998, 139:1329-1337.
15. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci 1998, 95:3597-3602.
16. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci 1999, 96:3540-3545.
17. Lacey D.L., Tan H.L., Lu J., et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000, 157:435-448.
18. Burgess T.L., Qian Y., Kaufman S., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999, 145:527-538.
19. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
20. Hofbauer L.C., Khosla S., Dunstan C.R., et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367-4370.
21. Chen X.W., Garner S.C., Anderson J.J. Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. Biochem Biophys Res Commun 2002, 295:417-422.
22. Bord S., Ireland D.C., Beavan S.R., Compston J.E. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 2003, 32:136-141.
23. Frost H.M. Osteoporosis: a hard look. J Am Geriatr Soc 1960, 8:568-571.
24. Martin R.B., Burr D.B. A hypothetical mechanism for the stimulation of osteonal remodelling by fatigue damage. J Biomech 1982, 15:137-139.
25. Burr D.B. The contribution of the organic matrix to bone's material properties. Bone 2002, 31:8-11.
26. Bentolila V., Boyce T.M., Fyhrie D.P., et al. Intracortical remodeling in adult rat long bones after fatigue loading. Bone 1998, 23:275-281.
27. Barrett J.G., Sample S.J., McCarthy J., et al. Effect of short-term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats. J Orthop Res 2007, 25:1070-1077.
28. Norman T.L., Yeni Y.N., Brown C.U., Wang Z. Influence of microdamage on fracture toughness of the human femur and tibia. Bone 1998, 23:303-306.
29. Allen M.R., Burr D.B. Skeletal microdamage: less about biomechanics and more about remodeling. Clin Rev Bone Miner Metab 2008, 6:24-30.
30. Bekker P.J., Holloway D., Nakanishi A., et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001, 16:348-360.
31. Prolia (denosumab) 2010, [prescribing information], Amgen Inc, Thousand Oaks, Calif.
32. European Public Assessment Report. Prolia™ 2010, European Medicines Agency, European Medicines Agency, London, United Kingdom.
33. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008, 29:155-192.
34. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12:1260-1268.
35. Mizuno A., Amizuka N., Irie K., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998, 247:610-615.
36. Ominsky M.S., Stolina M., Li X., et al. One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength. J Bone Miner Res 2009, 24:1234-1246.
37. Kong Y.Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
38. Lloyd S.A., Yuan Y.Y., Kostenuik P.J., et al. Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Calcif Tissue Int 2008, 82:361-372.
39. Kostenuik P.J., Nguyen H.Q., McCabe J., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009, 24:182-195.
40. Sobacchi C., Frattini A., Guerrini M.M., et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007, 39:960-962.
41. Crockett J.C., Mellis D.J., Scott D.I., Helfrich M.H. New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis. Osteoporos Int 2011, 22:1-20.
42. Nakagawa N., Kinosaki M., Yamaguchi K., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998, 253:395-400.
43. Dougall W.C., Glaccum M., Charrier K., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13:2412-2424.
44. Li J., Sarosi I., Yan X.Q., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci 2000, 97:1566-1571.
45. Roodman G.D., Dougall W.C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 2008, 34:92-101.
46. Kostenuik P.J. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 2005, 5:618-625.
47. Ominsky M.S., Li X., Asuncion F.J., et al. RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats. J Bone Miner Res 2008, 23:672-682.
48. Pierroz D.D., Bonnet N., Baldock P.A., et al. Are osteoclasts needed for the bone anabolic response to parathyroid hormone?. A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem 2010, 285:28164-28173.
49. Ominsky M.S., Stouch B., Schroeder J., et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone 2011, 49:162-173.
50. Kostenuik P.J., Smith S.Y., Jolette J., et al. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 2011, 49:151-161.
51. Erben R.G., Eberle J., Stahr K., Goldberg M. Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study. J Bone Miner Res 2000, 15:1085-1098.
52. Vandenput L., Boonen S., Van Herck E., et al. Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone. J Bone Miner Res 2002, 17:2080-2086.
53. Proell V., Xu H., Schuler C., et al. Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. Bone 2009, 45:677-681.
54. Li X., Ominsky M.S., Stolina M., et al. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone 2009, 45:669-676.
55. Kawano H., Sato T., Yamada T., et al. Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A 2003, 100:9416-9421.
56. Taxel P., Kaneko H., Lee S.K., et al. Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study. Osteoporos Int 2008, 19:193-199.
57. Anderson D.M., Maraskovsky E., Billingsley W.L., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
58. Seshasayee D., Wang H., Lee W.P., et al. A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J Biol Chem 2004, 279:30202-30209.
59. Stolina M., Guo J., Faggioni R., et al. Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin Immunol 2003, 109:347-354.
60. Yun T.J., Tallquist M.D., Aicher A., et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001, 166:1482-1491.
61. Ferrari-Lacraz S., Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity?. Osteoporos Int 2011, 22:435-446.
62. Bachmann M.F., Wong B.R., Josien R., et al. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 1999, 189:1025-1031.
63. Ashcroft A.J., Cruickshank S.M., Croucher P.I., et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 2003, 19:849-861.
64. Sutjandra L., Rodriguez R.D., Doshi S., et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet 2011, 50:793-807.
65. Jang G., Peterson M. Denosumab an inhibitor of RANKL has pharmacokinetics similiar to other monoclonal antibodies. J Bone Miner Res 2006, 21(Suppl 1):S190. Abstract SA403.
66. Bekker P.J., Holloway D.L., Rasmussen A.S., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059-1066.
67. Brown J.P., Prince R.L., Deal C., et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24:153-161.
68. Kendler D.L., Roux C., Benhamou C.L., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010, 25:72-81.
69. Miller P.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
70. Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
71. Eastell R., Christiansen C., Grauer A., et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011, 26:530-537.
72. Bone H.G., Bolognese M.A., Yuen C.K., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008, 93:2149-2157.
73. Beck T.J., Lewiecki E.M., Miller P.D., et al. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 2008, 11:351-359.
74. Genant H.K., Engelke K., Hanley D.A., et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010, 47:131-139.
75. Seeman E., Delmas P.D., Hanley D.A., et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010, 25:1886-1894.
76. Reid I.R., Miller P.D., Brown J.P., et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010, 25:2256-2265.
77. Boonen S., Adachi J.D., Man Z., et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011, 96:1727-1736.
78. Bone H.G., Bolognese M.A., Yuen C.K., et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011, 96:972-980.
79. Watts N.B., Roux C., Modlin J.F., et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?. Osteoporos Int 2012, 23:327-337.
80. Jamal S.A., Ljunggren O., Stehman-Breen C., et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011, 26:1829-1835.
81. Papapoulos S., Chapurlat R., Libanati C., et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012, 27:694-701.
82. McClung M., Lewiecki E.M., Bolognese M.A., et al. Effects on denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. J Bone Miner Res 2011, 24(Suppl 1):S20. Abstract 1061.
83. Moen M.D., Keam S.J. Spotlight on denosumab in postmenopausal osteoporosis. BioDrugs 2011, 25:261-264.
84. Lewiecki E.M. Treatment of osteoporosis with denosumab. Maturitas 2010, 66:182-186.